124 related articles for article (PubMed ID: 24333628)
1. Oligomeric bile acid-mediated oral delivery of low molecular weight heparin.
Al-Hilal TA; Park J; Alam F; Chung SW; Park JW; Kim K; Kwon IC; Kim IS; Kim SY; Byun Y
J Control Release; 2014 Feb; 175():17-24. PubMed ID: 24333628
[TBL] [Abstract][Full Text] [Related]
2. Prevention effect of orally active heparin conjugate on cancer-associated thrombosis.
Al-Hilal TA; Alam F; Park JW; Kim K; Kwon IC; Ryu GH; Byun Y
J Control Release; 2014 Dec; 195():155-61. PubMed ID: 24862320
[TBL] [Abstract][Full Text] [Related]
3. Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant.
Kim SK; Lee DY; Lee E; Lee YK; Kim CY; Moon HT; Byun Y
J Control Release; 2007 Jul; 120(1-2):4-10. PubMed ID: 17490773
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys.
Lee YK; Kim SK; Lee DY; Lee S; Kim CY; Shin HC; Moon HT; Byun Y
J Control Release; 2006 Apr; 111(3):290-8. PubMed ID: 16497407
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic evaluation of an oral tablet form of low-molecular-weight heparin and deoxycholic acid conjugate as a novel oral anticoagulant.
Park JW; Jeon OC; Kim SK; Al-Hilal TA; Lim KM; Moon HT; Kim CY; Byun Y
Thromb Haemost; 2011 Jun; 105(6):1060-71. PubMed ID: 21437357
[TBL] [Abstract][Full Text] [Related]
6. A newly developed oral heparin derivative for deep vein thrombosis: non-human primate study.
Kim SK; Lee DY; Kim CY; Nam JH; Moon HT; Byun Y
J Control Release; 2007 Nov; 123(2):155-63. PubMed ID: 17884230
[TBL] [Abstract][Full Text] [Related]
7. Tricaprylin microemulsion for oral delivery of low molecular weight heparin conjugates.
Kim SK; Lee EH; Vaishali B; Lee S; Lee YK; Kim CY; Moon HT; Byun Y
J Control Release; 2005 Jun; 105(1-2):32-42. PubMed ID: 15925422
[TBL] [Abstract][Full Text] [Related]
8. High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives.
Park JW; Jeon OC; Kim SK; Al-Hilal TA; Jin SJ; Moon HT; Yang VC; Kim SY; Byun Y
J Control Release; 2010 Dec; 148(3):317-26. PubMed ID: 20869408
[TBL] [Abstract][Full Text] [Related]
9. Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery.
Fan W; Xia D; Zhu Q; Li X; He S; Zhu C; Guo S; Hovgaard L; Yang M; Gan Y
Biomaterials; 2018 Jan; 151():13-23. PubMed ID: 29055774
[TBL] [Abstract][Full Text] [Related]
10. Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent.
Lee Y; Nam JH; Shin HC; Byun Y
Circulation; 2001 Dec; 104(25):3116-20. PubMed ID: 11748110
[TBL] [Abstract][Full Text] [Related]
11. Oral delivery of chemical conjugates of heparin and deoxycholic acid in aqueous formulation.
Kim SK; Vaishali B; Lee E; Lee S; Lee YK; Kumar TS; Moon HT; Byun Y
Thromb Res; 2006; 117(4):419-27. PubMed ID: 15913716
[TBL] [Abstract][Full Text] [Related]
12. Prevention effect of orally active heparin derivative on deep vein thrombosis.
Kim SK; Lee DY; Kim CY; Moon HT; Byun Y
Thromb Haemost; 2006 Aug; 96(2):149-53. PubMed ID: 16894457
[TBL] [Abstract][Full Text] [Related]
13. Anticoagulant efficacy of solid oral formulations containing a new heparin derivative.
Park JW; Jeon OC; Kim SK; Al-Hilal TA; Moon HT; Kim CY; Byun Y
Mol Pharm; 2010 Jun; 7(3):836-43. PubMed ID: 20349950
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT).
Lozano E; Monte MJ; Briz O; Hernández-Hernández A; Banales JM; Marin JJ; Macias RI
J Control Release; 2015 Oct; 216():93-102. PubMed ID: 26278512
[TBL] [Abstract][Full Text] [Related]
15. Orally active desulfated low molecular weight heparin and deoxycholic acid conjugate, 6ODS-LHbD, suppresses neovascularization and bone destruction in arthritis.
Hwang SR; Seo DH; Al-Hilal TA; Jeon OC; Kang JH; Kim SH; Kim HS; Chang YT; Kang YM; Yang VC; Byun Y
J Control Release; 2012 Nov; 163(3):374-84. PubMed ID: 23041275
[TBL] [Abstract][Full Text] [Related]
16. Chitosan nanoconstructs for improved oral delivery of low molecular weight heparin: In vitro and in vivo evaluation.
Paliwal R; Paliwal SR; Agrawal GP; Vyas SP
Int J Pharm; 2012 Jan; 422(1-2):179-84. PubMed ID: 22079712
[TBL] [Abstract][Full Text] [Related]
17. Oral heparin delivery: design and in vivo evaluation of a stomach-targeted mucoadhesive delivery system.
Schmitz T; Leitner VM; Bernkop-Schnürch A
J Pharm Sci; 2005 May; 94(5):966-73. PubMed ID: 15793802
[TBL] [Abstract][Full Text] [Related]
18. Glucuronidation converting methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate (S-8921) to a potent apical sodium-dependent bile acid transporter inhibitor, resulting in a hypocholesterolemic action.
Sakamoto S; Kusuhara H; Miyata K; Shimaoka H; Kanazu T; Matsuo Y; Nomura K; Okamura N; Hara S; Horie K; Baba T; Sugiyama Y
J Pharmacol Exp Ther; 2007 Aug; 322(2):610-8. PubMed ID: 17470645
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic efficacy of an oral low molecular weight heparin conjugated with deoxycholic asset on microsurgical anastomosis in rats.
Eom JS; Koh KS; Al-Hilal TA; Park JW; Jeon OC; Moon HT; Byun Y
Thromb Res; 2010 Sep; 126(3):e220-4. PubMed ID: 20619883
[TBL] [Abstract][Full Text] [Related]
20. Secretin activation of the apical Na+-dependent bile acid transporter is associated with cholehepatic shunting in rats.
Alpini G; Glaser S; Baiocchi L; Francis H; Xia X; Lesage G
Hepatology; 2005 May; 41(5):1037-45. PubMed ID: 15834929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
